Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer

Cheng Yi Lin, Ching Yih Lin, I. Wei Chang, Ming Jen Sheu, Chien Feng Li, Sung Wei Lee, Li Ching Lin, Ying En Lee, Hong Lin He

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery is the mainstay of treatment for locally advanced rectal cancer. Several heparin-binding associated proteins have been reported to play a critical role in cancer progression. However, the clinical relevancies of such proteins and their associations with CCRT response in rectal cancer have not yet to be fully elucidated. Methods: The analysis of a public transcriptome of rectal cancer indicated that thrombospondin 2 (THBS2) is a predictive factor for CCRT response. Immunohistochemical analyses were conducted to evaluate the expression of THBS2 in pretreatment biopsy specimens from rectal cancer patients without distant metastasis. Furthermore, the relationships between THBS2 expression and various clinicopathological factors or survival were analyzed. Results: Low expression of THBS2 was significantly associated with advanced pretreatment tumor (P<0.001) and nodal status (P=0.004), post-treatment tumor (P<0.001) and nodal status (P<0.001), increased vascular invasion (P=0.003), increased perineural invasion (P=0.023) and inferior tumor regression grade (P=0.015). In univariate analysis, low THBS2 expression predicted worse outcomes for disease-free survival, local recurrence-free survival and metastasis-free survival (all P<0.001). In multivariate analysis, low expression of THBS2 still served as a negative prognostic factor for disease-free survival (Hazard ratio=3.057, P=0.002) and metastasis-free survival (Hazard ratio=3.362, P=0.012). Conclusion: Low THBS2 expression was correlated with advanced disease status and low tumor regression after preoperative CCRT and that it acted as an independent negative prognostic factor in rectal cancer. THBS2 may represent a predictive biomarker for CCRT response in rectal cancer.

Original languageEnglish
Pages (from-to)2423-2432
Number of pages10
JournalAmerican Journal of Translational Research
Volume7
Issue number11
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Chemoradiotherapy
Rectal Neoplasms
Tumors
Neoplasms
Survival
Neoplasm Metastasis
Disease-Free Survival
Hazards
thrombospondin 2
Biopsy
Biomarkers
Transcriptome
Surgery
Blood Vessels
Heparin
Proteins
Multivariate Analysis

Keywords

  • Chemoradiotherapy
  • Concurrent chemoradiotherapy (CCRT)
  • Rectal cancer
  • Thrombospondin 2 (THBS2)

ASJC Scopus subject areas

  • Molecular Medicine
  • Clinical Biochemistry
  • Cancer Research

Cite this

Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer. / Lin, Cheng Yi; Lin, Ching Yih; Chang, I. Wei; Sheu, Ming Jen; Li, Chien Feng; Lee, Sung Wei; Lin, Li Ching; Lee, Ying En; He, Hong Lin.

In: American Journal of Translational Research, Vol. 7, No. 11, 01.01.2015, p. 2423-2432.

Research output: Contribution to journalArticle

Lin, Cheng Yi ; Lin, Ching Yih ; Chang, I. Wei ; Sheu, Ming Jen ; Li, Chien Feng ; Lee, Sung Wei ; Lin, Li Ching ; Lee, Ying En ; He, Hong Lin. / Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer. In: American Journal of Translational Research. 2015 ; Vol. 7, No. 11. pp. 2423-2432.
@article{d32485b50e524e90b46bd2009d41deb0,
title = "Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer",
abstract = "Background: Neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery is the mainstay of treatment for locally advanced rectal cancer. Several heparin-binding associated proteins have been reported to play a critical role in cancer progression. However, the clinical relevancies of such proteins and their associations with CCRT response in rectal cancer have not yet to be fully elucidated. Methods: The analysis of a public transcriptome of rectal cancer indicated that thrombospondin 2 (THBS2) is a predictive factor for CCRT response. Immunohistochemical analyses were conducted to evaluate the expression of THBS2 in pretreatment biopsy specimens from rectal cancer patients without distant metastasis. Furthermore, the relationships between THBS2 expression and various clinicopathological factors or survival were analyzed. Results: Low expression of THBS2 was significantly associated with advanced pretreatment tumor (P<0.001) and nodal status (P=0.004), post-treatment tumor (P<0.001) and nodal status (P<0.001), increased vascular invasion (P=0.003), increased perineural invasion (P=0.023) and inferior tumor regression grade (P=0.015). In univariate analysis, low THBS2 expression predicted worse outcomes for disease-free survival, local recurrence-free survival and metastasis-free survival (all P<0.001). In multivariate analysis, low expression of THBS2 still served as a negative prognostic factor for disease-free survival (Hazard ratio=3.057, P=0.002) and metastasis-free survival (Hazard ratio=3.362, P=0.012). Conclusion: Low THBS2 expression was correlated with advanced disease status and low tumor regression after preoperative CCRT and that it acted as an independent negative prognostic factor in rectal cancer. THBS2 may represent a predictive biomarker for CCRT response in rectal cancer.",
keywords = "Chemoradiotherapy, Concurrent chemoradiotherapy (CCRT), Rectal cancer, Thrombospondin 2 (THBS2)",
author = "Lin, {Cheng Yi} and Lin, {Ching Yih} and Chang, {I. Wei} and Sheu, {Ming Jen} and Li, {Chien Feng} and Lee, {Sung Wei} and Lin, {Li Ching} and Lee, {Ying En} and He, {Hong Lin}",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "2423--2432",
journal = "American Journal of Translational Research",
issn = "1943-8141",
publisher = "e-Century Publishing Corporation",
number = "11",

}

TY - JOUR

T1 - Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer

AU - Lin, Cheng Yi

AU - Lin, Ching Yih

AU - Chang, I. Wei

AU - Sheu, Ming Jen

AU - Li, Chien Feng

AU - Lee, Sung Wei

AU - Lin, Li Ching

AU - Lee, Ying En

AU - He, Hong Lin

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery is the mainstay of treatment for locally advanced rectal cancer. Several heparin-binding associated proteins have been reported to play a critical role in cancer progression. However, the clinical relevancies of such proteins and their associations with CCRT response in rectal cancer have not yet to be fully elucidated. Methods: The analysis of a public transcriptome of rectal cancer indicated that thrombospondin 2 (THBS2) is a predictive factor for CCRT response. Immunohistochemical analyses were conducted to evaluate the expression of THBS2 in pretreatment biopsy specimens from rectal cancer patients without distant metastasis. Furthermore, the relationships between THBS2 expression and various clinicopathological factors or survival were analyzed. Results: Low expression of THBS2 was significantly associated with advanced pretreatment tumor (P<0.001) and nodal status (P=0.004), post-treatment tumor (P<0.001) and nodal status (P<0.001), increased vascular invasion (P=0.003), increased perineural invasion (P=0.023) and inferior tumor regression grade (P=0.015). In univariate analysis, low THBS2 expression predicted worse outcomes for disease-free survival, local recurrence-free survival and metastasis-free survival (all P<0.001). In multivariate analysis, low expression of THBS2 still served as a negative prognostic factor for disease-free survival (Hazard ratio=3.057, P=0.002) and metastasis-free survival (Hazard ratio=3.362, P=0.012). Conclusion: Low THBS2 expression was correlated with advanced disease status and low tumor regression after preoperative CCRT and that it acted as an independent negative prognostic factor in rectal cancer. THBS2 may represent a predictive biomarker for CCRT response in rectal cancer.

AB - Background: Neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery is the mainstay of treatment for locally advanced rectal cancer. Several heparin-binding associated proteins have been reported to play a critical role in cancer progression. However, the clinical relevancies of such proteins and their associations with CCRT response in rectal cancer have not yet to be fully elucidated. Methods: The analysis of a public transcriptome of rectal cancer indicated that thrombospondin 2 (THBS2) is a predictive factor for CCRT response. Immunohistochemical analyses were conducted to evaluate the expression of THBS2 in pretreatment biopsy specimens from rectal cancer patients without distant metastasis. Furthermore, the relationships between THBS2 expression and various clinicopathological factors or survival were analyzed. Results: Low expression of THBS2 was significantly associated with advanced pretreatment tumor (P<0.001) and nodal status (P=0.004), post-treatment tumor (P<0.001) and nodal status (P<0.001), increased vascular invasion (P=0.003), increased perineural invasion (P=0.023) and inferior tumor regression grade (P=0.015). In univariate analysis, low THBS2 expression predicted worse outcomes for disease-free survival, local recurrence-free survival and metastasis-free survival (all P<0.001). In multivariate analysis, low expression of THBS2 still served as a negative prognostic factor for disease-free survival (Hazard ratio=3.057, P=0.002) and metastasis-free survival (Hazard ratio=3.362, P=0.012). Conclusion: Low THBS2 expression was correlated with advanced disease status and low tumor regression after preoperative CCRT and that it acted as an independent negative prognostic factor in rectal cancer. THBS2 may represent a predictive biomarker for CCRT response in rectal cancer.

KW - Chemoradiotherapy

KW - Concurrent chemoradiotherapy (CCRT)

KW - Rectal cancer

KW - Thrombospondin 2 (THBS2)

UR - http://www.scopus.com/inward/record.url?scp=84950110420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950110420&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 2423

EP - 2432

JO - American Journal of Translational Research

JF - American Journal of Translational Research

SN - 1943-8141

IS - 11

ER -